Clinical Trial Update: Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial of ramucirumab plus best supportive care in gastric cancer and adenocarcinoma completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Gastric Cancer, Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2014-10-16